Advertisement
| columbia alzheimer's study: Mind Thief Han Yu, 2021-03-02 Alzheimer’s disease, a haunting and harrowing ailment, is one of the world’s most common causes of death. Alzheimer’s lingers for years, with patients’ outward appearance unaffected while their cognitive functions fade away. Patients lose the ability to work and live independently, to remember and recognize. There is still no proven way to treat Alzheimer’s because its causes remain unknown. Mind Thief is a comprehensive and engaging history of Alzheimer’s that demystifies efforts to understand the disease. Beginning with the discovery of “presenile dementia” in the early twentieth century, Han Yu examines over a century of research and controversy. She presents the leading hypotheses for what causes Alzheimer’s; discusses each hypothesis’s tangled origins, merits, and gaps; and details their successes and failures. Yu synthesizes a vast amount of medical literature, historical studies, and media interviews, telling the gripping stories of researchers’ struggles while situating science in its historical, social, and cultural contexts. Her chronicling of the trajectory of Alzheimer’s research deftly balances rich scientific detail with attention to the wider implications. In narrating the attempts to find a treatment, Yu also offers a critical account of research and drug development and a consideration of the philosophy of aging. Wide-ranging and accessible, Mind Thief is an important book for all readers interested in the challenge of Alzheimer’s. |
| columbia alzheimer's study: The Aging Brain , 2016 Growing older may be inevitable, but mental decline is not. Find out what science has to say about how your brain changes over time.-- |
| columbia alzheimer's study: Behavioral Neurology & Neuropsychiatry David B. Arciniegas, C. Alan Anderson, Christopher M. Filley, 2013-01-24 The merger of behavioral neurology and neuropsychiatry into a single medical subspecialty, Behavioral Neurology & Neuropsychiatry, requires an understanding of brain-behavior relationships and a clinical approach that transcends the traditional perspectives of neurology and psychiatry. Designed as a primer of concepts and principles, and authored by a multidisciplinary group of internationally known clinical neuroscientists, this book divides into three sections: • Structural and Functional Neuroanatomy (Section I) addresses the neuroanatomy and phenomenology of cognition, emotion, and behavior • Clinical Assessment (Section II) describes neuropsychiatric history taking, neurological and mental status examinations, neuropsychological assessment, and neuroimaging, electrophysiologic, and laboratory methods • Treatment (Section III) discusses environmental, behavioral, rehabilitative, psychological, social, pharmacological, and procedural interventions for cognitive, emotional, and behavioral disorders. By emphasizing the principles of Behavioral Neurology & Neuropsychiatry, this book will improve your understanding of brain-behavior relationships and inform your care of patients and families affected by neurobehavioral disorders. |
| columbia alzheimer's study: Outsmarting Alzheimer's Kenneth S. Kosik, 2015-12-29 Understand the six keys to protecting brain health, personalize your 3-week plan based on the latest science, make fun and easy lifestyle changes. |
| columbia alzheimer's study: Forgetting Scott A. Small, 2021-07-13 “Fascinating and useful . . . The distinguished memory researcher Scott A. Small explains why forgetfulness is not only normal but also beneficial.”—Walter Isaacson, bestselling author of The Code Breaker and Leonardo da Vinci Who wouldn’t want a better memory? Dr. Scott Small has dedicated his career to understanding why memory forsakes us. As director of the Alzheimer’s Disease Research Center at Columbia University, he focuses largely on patients who experience pathological forgetting, and it is in contrast to their suffering that normal forgetting, which we experience every day, appears in sharp relief. Until recently, most everyone—memory scientists included—believed that forgetting served no purpose. But new research in psychology, neurobiology, medicine, and computer science tells a different story. Forgetting is not a failure of our minds. It’s not even a benign glitch. It is, in fact, good for us—and, alongside memory, it is a required function for our minds to work best. Forgetting benefits our cognitive and creative abilities, emotional well-being, and even our personal and societal health. As frustrating as a typical lapse can be, it’s precisely what opens up our minds to making better decisions, experiencing joy and relationships, and flourishing artistically. From studies of bonobos in the wild to visits with the iconic painter Jasper Johns and the renowned decision-making expert Daniel Kahneman, Small looks across disciplines to put new scientific findings into illuminating context while also revealing groundbreaking developments about Alzheimer’s disease. The next time you forget where you left your keys, remember that a little forgetting does a lot of good. |
| columbia alzheimer's study: The Spectrum of Hope Gayatri Devi, 2017-10-31 Imagine finding a glimmer of good news in a diagnosis of Alzheimer’s. And imagine how that would change the outlook of the 5 million Americans who suffer from Alzheimer’s disease and other dementias, not to mention their families, loved ones, and caretakers. A neurologist who’s been specializing in dementia and memory loss for more than 20 years, Dr. Gayatri Devi rewrites the story of Alzheimer’s by defining it as a spectrum disorder—like autism, Alzheimer’s is a disease that affects different people differently. She encourages people who are worried about memory impairment to seek a diagnosis, because early treatment will enable doctors and caregivers to manage the disease more effectively through drugs and other therapies. Told through the stories of Dr. Devi’s patients, The Spectrum of Hope humanizes the science, and offers equal parts practical advice and wisdom with skillful ease, along with real hope. Here are chapters on how to maintain independence and dignity; how to fight depression, anxiety, and apathy; how to communicate effectively with a person suffering from dementia. Plus chapters on sexuality, genetics, going public with the diagnosis, even putting together a bucket list—because through her practice, Dr. Devi knows that the majority of Alzheimer’s patients continue to live and work in their communities. They babysit their grandkids, drive to the store (or own the store), serve their clients, or otherwise live fulfilling lives. That’s news that 5 million people are waiting to hear. |
| columbia alzheimer's study: Brain Banking , 2018-02-27 Brain Banking, Volume 150, serves as the only book on the market offering comprehensive coverage of the functional realities of brain banking. It focuses on brain donor recruitment strategies, brain bank networks, ethical issues, brain dissection/tissue processing/tissue dissemination, neuropathological diagnosis, brain donor data, and techniques in brain tissue analysis. In accordance with massive initiatives, such as BRAIN and the EU Human Brain Project, abnormalities and potential therapeutic targets of neurological and psychiatric disorders need to be validated in human brain tissue, thus requiring substantial numbers of well characterized human brains of high tissue quality with neurological and psychiatric diseases. - Offers comprehensive coverage of the functional realities of brain banking, with a focus on brain donor recruitment strategies, brain bank networks, ethical issues, and more - Serves as a valuable resource for staff in existing brain banks by highlighting best practices - Enhances the sharing of expertise between existing banks and highlights a range of techniques applicable to banked tissue for neuroscience researchers - Authored by leaders from brain banks around the globe – the broadest, most expert coverage available |
| columbia alzheimer's study: Cyclin Dependent Kinase 5 (Cdk5) Nancy Y. Ip, Li-Huei Tsai, 2009-02-28 Cyclin Dependent Kinase 5 provides a comprehensive and up-to-date collection of reviews on the discovery, signaling mechanisms and functions of Cdk5, as well as the potential implication of Cdk5 in the treatment of neurodegenerative diseases. Since the identification of this unique member of the Cdk family, Cdk5 has emerged as one of the most important signal transduction mediators in the development, maintenance and fine-tuning of neuronal functions and networking. Further studies have revealed that Cdk5 is also associated with the regulation of neuronal survival during both developmental stages and in neurodegenerative diseases. These observations indicate that precise control of Cdk5 is essential for the regulation of neuronal survival. The pivotal role Cdk5 appears to play in both the regulation of neuronal survival and synaptic functions thus raises the interesting possibility that Cdk5 inhibitors may serve as therapeutic treatment for a number of neurodegenerative diseases. |
| columbia alzheimer's study: The First Cell Azra Raza, 2019-10-15 With the fascinating scholarship of The Emperor of All Maladies and the deeply personal experience of When Breath Becomes Air, a world-class oncologist examines the current state of cancer and its devastating impact on the individuals it affects -- including herself. In The First Cell, Azra Raza offers a searing account of how both medicine and our society (mis)treats cancer, how we can do better, and why we must. A lyrical journey from hope to despair and back again, The First Cell explores cancer from every angle: medical, scientific, cultural, and personal. Indeed, Raza describes how she bore the terrible burden of being her own husband's oncologist as he succumbed to leukemia. Like When Breath Becomes Air, The First Cell is no ordinary book of medicine, but a book of wisdom and grace by an author who has devoted her life to making the unbearable easier to bear. |
| columbia alzheimer's study: The Alzheimer's Solution Dean Sherzai, Ayesha Sherzai, 2017-10-05 THE HIGHLY SUCCESSFUL, PROVEN PROGRAMME FOR REVERSING THE SYMPTOMS OF ALZHEIMER'S DISEASE Alzheimer's Disease affects over 47 million people worldwide but 90 per cent of cases can be prevented. Based on the largest clinical study to date, The Alzheimer's Solution, by leading neurologists and Alzheimer's specialists Drs Dean and Ayesha Sherzai, provides the essential practical tools you and your family need to reverse the symptoms and prevent cognitive decline. Alzheimer's disease isn't a genetic inevitability and a diagnosis doesn’t need to spell the end. Ninety per cent of us can avoid getting it and for the 10 per cent with strong genetic risk, the disease can be delayed by 10 to 15 years. This is based on the remarkable results Dr Dean Sherzai and Dr Ayesha Sherzai have seen in their own clinic. This much-needed revolutionary book provides: *The groundbreaking and successful programme for the treatment of Alzheimer's *A practical 5-part plan for reversing and preventing Alzheimer's, covering food, sleep, exercise, stress-management and activities that keep your brain healthy *A questionnaire for assessing your risk level and daily guides for optimising your brain's health *Delicious and simple brain-healthy recipes for you and the family to enjoy Praise for The Alzheimer's Solution: 'The Sherzais' research is changing the landscape of neurodegenerative diseases as well as the outcomes for thousands of patients.' Dr Keith Black, Chairman of the Neurosurgery Department and Director of the Maxine Dunitz Neurological Institute, Cedars-Sinai Medical Center 'A very important book.' Dr Dilip Jeste, Distinguished Professor of Psychiatry and Neurosciences, University of California, San Diego School of Medicine 'The Alzheimer’s Solution supplies everything you need to know about the prevention of this disease' Dr Joel Fuhrman, New York Times best-selling author of Super Immunity, Eat to Live and The End of Diabetes, President, Nutritional Research Foundation 'This [is a] thorough, thoughtful, empowering, and timely book…Every family should own, and apply, The Alzheimer’s Solution.' Dr David Katz, founding director of Yale University's Yale-Griffin Prevention Research Center, founder and president of the True Health Initiative, and author of Disease-Proof |
| columbia alzheimer's study: Alzheimer’s Disease: Advances for a New Century IOS Press, 2013-02-15 This volume is a companion to the highly successful book published in association with the Journal of Alzheimer’s Disease (JAD) on the centennial of Alzheimer’s discovery: “Alzheimer’s Disease: A Century of Scientific and Clinical Research”. Instead of looking back, this collection, “Alzheimer’s Disease: Advances for a New Century”, will look forward. Using scientometric analysis the most promising developments since the Alzheimer Centennial in 2006 have been substantiated. While prior trends and advances in genetics, amyloid-?, tau, neuropathology, and oxidative stress continue as active areas, emergent areas impacting the transition from normal cognition to Alzheimer’s disease such as diagnostic imaging, biomarkers, metabolism, and lifestyle (areas conceived only a few years ago) now dominate the debate. Invited contributors have summarized their landmark publications identified by our analysis and have put them into perspective, explaining the impetus behind the work, the contribution of the results to the field, and who played a role in the work. |
| columbia alzheimer's study: The Tumor John Grisham, Focused Ultrasound Foundation, 2015-03 John Grisham says THE TUMOR is the most important book he has ever written. In this short book, he provides readers with a fictional account of how a real, new medical technology could revolutionize the future of medicine by curing with sound. THE TUMOR follows the present day experience of the fictional patient Paul, an otherwise healthy 35-year-old father who is diagnosed with a malignant brain tumor. Grisham takes readers through a detailed account of Paul’s treatment and his family’s experience that doesn’t end as we would hope. Grisham then explores an alternate future, where Paul is diagnosed with the same brain tumor at the same age, but in the year 2025, when a treatment called focused ultrasound is able to extend his life expectancy. Focused ultrasound has the potential to treat not just brain tumors, but many other disorders, including Parkinson’s, Alzheimer’s, hypertension, and prostate, breast and pancreatic cancer. For more information or to order a free hardcopy of the book, please visit The Focused Ultrasound Foundation’s website www.fusfoundation.org. Here you will find a video of Grisham on the TEDx stage with the Foundation’s chairman and a Parkinson’s patient who brings the audience to its feet sharing her incredible story of a focused ultrasound “miracle.” Readers will get a taste of the narrative they expect from Grisham, but this short book will also educate and inspire people to be hopeful about the future of medical innovation. |
| columbia alzheimer's study: Alzheimer's In America Maria Shriver, 2011-04-12 The Shriver Report: A Woman’s Nation Takes on Alzheimer’s will be the first comprehensive multi-disciplinary look at these questions at this transformational moment. The Report will digest the current trends in thinking about Alzheimer’s, examine cutting-edge medical research, look at societal impacts, and include a groundbreaking and comprehensive national poll. It will feature original photography and personal essays by men and women – some from the public arena with names you know, some from everyday America – sharing their personal struggles with the disease as patients, caregivers and family members. |
| columbia alzheimer's study: A Tattoo on my Brain Daniel Gibbs, Teresa H. Barker, 2023-03-16 Dr Daniel Gibbs is one of 50 million people worldwide with an Alzheimer's disease diagnosis. Unlike most patients with Alzheimer's, however, Dr Gibbs worked as a neurologist for twenty-five years, caring for patients with the very disease now affecting him. Also unusual is that Dr Gibbs had begun to suspect he had Alzheimer's several years before any official diagnosis could be made. Forewarned by genetic testing showing he carried alleles that increased the risk of developing the disease, he noticed symptoms of mild cognitive impairment long before any tests would have alerted him. In this highly personal account, Dr Gibbs documents the effect his diagnosis has had on his life and explains his advocacy for improving early recognition of Alzheimer's. Weaving clinical knowledge from decades caring for dementia patients with his personal experience of the disease, this is an optimistic tale of one man's journey with early-stage Alzheimer's disease. Soon to be a documentary film on MTV/Paramount +. |
| columbia alzheimer's study: Last Dance at the Savoy Kathryn Leigh Scott, 2016-02-25 When Kathryn Leigh Scott's husband was diagnosed with progressive supranuclear palsy (PSP), a neurological disease for which there is (so far) no cure, it was a devastating time for both of them, not least because so little is known about the cause or treatment of a disease that affects some 20,000 Americans, a number similar to that of Lou Gehrig's disease (ALS). Last Dance at the Savoy is both a personal story about Scott's husband, Geoff Miller, the founding editor of Los Angeles magazine, who lived life fully despite having a terminal illness, and a sharing of her insights on dealing with the day-to-day issues of caring for someone with a progressive neurological condition. Scott often yearned for someone to figuratively take my hand and walk with me through the difficult times; I hope through this book I can reach out to you with encouragement and practical advice. Last Dance at the Savoy includes a resource guide that provides facts about prime-of-life diseases; contact information for support organizations, research studies and clinical trials; where to find handicap products and equipment; and recommended caregiving publications and family conferences. Contains a foreword by Yvette Bordelon, MD, PhD, a neurologist at UCLA whose clinical work involves the diagnosis and treatment of movement disorders. A percentage of royalties from Last Dance at the Savoy are donated to CurePSP. |
| columbia alzheimer's study: Alzheimer's Disease Drug Development Jeffrey Cummings, Jefferson Kinney, Howard Fillit, 2022-03-31 Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models. |
| columbia alzheimer's study: Hospitalist Neurology Martin A. Samuels, 1999 Hospitalist Neurology, in the highly regarded Blue Books of Practical Neurology series, focuses on the clinical practice of in-patient neurology as well as the neurologic sequelae of non-neurologic conditions of hospitalized patients. It is meant to provide consulting hospital-based neurologists with a rational approach to evaluating neurological problems in a busy general hospital. |
| columbia alzheimer's study: Navigating Life with Dementia James M. Noble, 2022 Since you have opened this book, you or a close friend or family member have likely been impacted by the upsetting and frightening diagnosis of dementia. You may have been told about this diagnosis in a number of different ways. Either the term dementia was used, or other words associated with or more specific than dementia, such as Alzheimer's disease, vascular dementia, Lewy Body disease, frontotemporal dementia, or Pick's disease, were used. You may even have been misinformed at first and told that you were simply facing the normal changes of aging, such as forgetfulness or mild depression. Sometimes these terms are relatable based on others we know who have been affected by them. But they can be shocking to hear and hard to understand when talking about yourself or a loved one. Even more difficult is that none of the most common forms of dementia currently have treatments that can cure or slow the disease-- |
| columbia alzheimer's study: Teleneurology Richard Wootton, Victor Patterson, 2005-04-12 Teleneurology refers to the use of telecommunications techniques such as the telephone, Internet, email, and videoconferencing to improve the delivery of neurology services. Containing 15 contributions from international clinicians, this volume provides an introduction to telemedicine as it is practiced in neurology today. It is divided into three sections: techniques, applications, and practical issues. Technical information has been kept to a minimum, as the emphasis is on the utility of each technique, rather than the technology itself. The editors are affiliated with the Center for Online Health at the U. of Queensland in Australia. Annotation :2005 Book News, Inc., Portland, OR (booknews.com). |
| columbia alzheimer's study: The Aging Nervous System Gabe J. Maletta, Francis J. Pirozzolo, 1980 |
| columbia alzheimer's study: Racial and Ethnic Differences in the Health of Older Americans National Research Council, Division of Behavioral and Social Sciences and Education, Commission on Behavioral and Social Sciences and Education, Committee on Population, 1997-09-23 Older Americans, even the oldest, can now expect to live years longer than those who reached the same ages even a few decades ago. Although survival has improved for all racial and ethnic groups, strong differences persist, both in life expectancy and in the causes of disability and death at older ages. This book examines trends in mortality rates and selected causes of disability (cardiovascular disease, dementia) for older people of different racial and ethnic groups. The determinants of these trends and differences are also investigated, including differences in access to health care and experiences in early life, diet, health behaviors, genetic background, social class, wealth and income. Groups often neglected in analyses of national data, such as the elderly Hispanic and Asian Americans of different origin and immigrant generations, are compared. The volume provides understanding of research bearing on the health status and survival of the fastest-growing segment of the American population. |
| columbia alzheimer's study: The Behavioral Neurology of Dementia Bruce L. Miller, Bradley F. Boeve, 2016-11-17 Distils the most valuable discoveries in dementia research into clear, insightful chapters written by international experts. |
| columbia alzheimer's study: Assessing Quality of Life in Alzheimer's Disease Steven Mark Albert, Rebecca G. Logsdon, 2000 |
| columbia alzheimer's study: Genome-Wide Association Studies Krishnarao Appasani, 2016-01-14 Experts from academia and industry highlight the potential of genome-wide association studies from basic science to clinical and biotechnological/pharmaceutical applications. |
| columbia alzheimer's study: Slow Dancing with a Stranger Meryl Comer, 2014-09-02 A New York Times Bestseller Emmy-award winning broadcast journalist and leading Alzheimer’s advocate Meryl Comer’s Slow Dancing With a Stranger is a profoundly personal, unflinching account of her husband’s battle with Alzheimer’s disease that serves as a much-needed wake-up call to better understand and address a progressive and deadly affliction. When Meryl Comer’s husband Harvey Gralnick was diagnosed with early onset Alzheimer’s disease in 1996, she watched as the man who headed hematology and oncology research at the National Institutes of Health started to misplace important documents and forget clinical details that had once been cataloged encyclopedically in his mind. With harrowing honesty, she brings readers face to face with this devastating condition and its effects on its victims and those who care for them. Detailing the daily realities and overwhelming responsibilities of caregiving, Comer sheds intensive light on this national health crisis, using her personal experiences—the mistakes and the breakthroughs—to put a face to a misunderstood disease, while revealing the facts everyone needs to know. Pragmatic and relentless, Meryl has dedicated herself to fighting Alzheimer’s and raising public awareness. “Nothing I do is really about me; it’s all about making sure no one ends up like me,” she writes. Deeply personal and illuminating, Slow Dancing With a Stranger offers insight and guidance for navigating Alzheimer’s challenges. It is also an urgent call to action for intensive research and a warning that we must prepare for the future, instead of being controlled by a disease and a healthcare system unable to fight it. |
| columbia alzheimer's study: Biomarkers in Psychiatry Judith Pratt, Jeremy Hall, 2019-01-05 This volume addresses one of the Holy Grails in Psychiatry, namely the evidence for and potential to adopt ‘Biomarkers’ for prevention, diagnosis, and treatment responses in mental health conditions. It meshes together state of the art research from international renowned pre-clinical and clinical scientists to illustrate how the fields of anxiety disorders, depression, psychotic disorders, and autism spectrum disorder have advanced in recent years. |
| columbia alzheimer's study: Brain Longevity Dharma Singh Khalsa, Cameron Stauth, 2001-01-01 In the tradition of Andrew Weil's bestseller Spontaneous Healing, this is a physician's breakthrough medical program for the brain designed to diminish the effect of memory impairment caused by stress, aging, and Alzheimer's disease. As we grow older and experience the stresses of life, at about age 40 many of us begin to have trouble remembering things, concentrating, and generally staying mentally sharp. This book contains a four-part program including nutritional, stress-relieving, pharmacological, and mind-body exercise therapies to help people overcome the undesirable effects of normal brain aging. By controlling cortisol, a hormone that is toxic to the brain and present in excessive levels as we age, Dr. Khalsa's plan can help improve memory and emotional zest. This is the first book to: Describe a program that may diminish age-associated memory impairment Feature a clinical method that can promote memory functioning impaired by Alzheimer's disease Detail the physical damage done to the brain by stress, how it adversely affects memory and our other mental abilities, and what can be done about it. |
| columbia alzheimer's study: Still Alice Lisa Genova, 2010-08-05 A moving story of a woman with early onset Alzheimer's disease, now a major Academy Award-winning film starring Julianne Moore and Kristen Stewart. Alice Howland is proud of the life she worked so hard to build. At fifty, she's a cognitive psychology professor at Harvard and a renowned expert in linguistics, with a successful husband and three grown children. When she begins to grow forgetful and disoriented, she dismisses it for as long as she can until a tragic diagnosis changes her life - and her relationship with her family and the world around her - for ever. Unable to care for herself, Alice struggles to find meaning and purpose as her concept of self gradually slips away. But Alice is a remarkable woman, and her family learn more about her and each other in their quest to hold on to the Alice they know. Her memory hanging by a frayed thread, she is living in the moment, living for each day. But she is still Alice. 'Remarkable … illuminating … highly relevant today' Daily Mail 'The most accurate account of what it feels like to be inside the mind of an Alzheimer's patient I've ever read. Beautifully written and very illuminating' Rosie Boycot 'Utterly brilliant' Chrissy Iley |
| columbia alzheimer's study: Environmental Epigenetics L. Joseph Su, Tung-chin Chiang, 2015-05-18 This book examines the toxicological and health implications of environmental epigenetics and provides knowledge through an interdisciplinary approach. Included in this volume are chapters outlining various environmental risk factors such as phthalates and dietary components, life states such as pregnancy and ageing, hormonal and metabolic considerations and specific disease risks such as cancer cardiovascular diseases and other non-communicable diseases. Environmental Epigenetics imparts integrative knowledge of the science of epigenetics and the issues raised in environmental epidemiology. This book is intended to serve both as a reference compendium on environmental epigenetics for scientists in academia, industry and laboratories and as a textbook for graduate level environmental health courses. Environmental Epigenetics imparts integrative knowledge of the science of epigenetics and the issues raised in environmental epidemiology. This book is intended to serve both as a reference compendium on environmental epigenetics for scientists in academia, industry and laboratories and as a textbook for graduate level environmental health courses. |
| columbia alzheimer's study: The Health Effects of Cannabis and Cannabinoids National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda, 2017-05-01 Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€that summarizes and prioritizes pressing research needs. |
| columbia alzheimer's study: The Disordered Mind Eric R. Kandel, 2018-09-27 Neurological and psychiatric disorders have long been regarded as fundamentally different, depending on whether they appear to affect the brain or the mind. In reality, the brain and the mind are inseparable. Both types of disorder can affect every aspect of brain function: from perception, action, memory and emotion to empathy, social interaction, attention and consciousness. It is easy to view brain disorders as simply tragic or frightening. However, studying where these functions go wrong provides a window on the workings of the healthy brain, and makes it more likely that scientists and clinicians will be able to develop effective treatments or preventative strategies. As individuals, and as a society, we are also able to better empathise with people with disorders of the mind. Building on his pioneering research, Eric R. Kandel illustrates how breakthrough studies of brain disruptions can deepen our understanding of thought, feeling, behaviour, memory and creativity, and perhaps in the future will transform medical care and lead to the development of a unified theory of mind. |
| columbia alzheimer's study: The Alzheimer's Prevention & Treatment Diet Richard S. Isaacson, Christopher N. Ochner, 2016 Alzheimer's disease (AD) is a type of dementia that can be very hard on both the patient and the caregiver. Currently, five million Americans have been diagnosed with AD--and that number is likely to triple by 2050. While the cause of Alzheimer's disease is still a mystery, new research has increased our knowledge of certain aspects of the disease. Perhaps most significant, studies show that proper diet may make a real difference, not only in slowing the progression of AD, but also in preventing it. In this groundbreaking book, a notable expert on Alzheimer's disease has teamed up with a leading researcher of nutrition to create a unique guide to understanding and managing this serious condition. The Alzheimer's Prevention and Treatment Diet outlines a cutting-edge nutritional program that will be of interest both to Alzheimer's patients and to anybody who wants to maintain optimal memory and mental agility for years to come. The book begins with an overview of Alzheimer's disease, outlining its symptoms, risk factors, diagnosis, and current treatment methods. You'll also learn how Alzheimer's disease differs from other forms of memory loss and cognitive impairment. Next, Drs. Isaacson and Ochner take a closer look at the impact of nutrition on your ability to think and remember, examining the effects of carbohydrates, fats, and proteins on the brain. Then, they share their innovative program for Alzheimer's prevention, showing you how to maximize your cognitive health through diet and exercise. Finally, the authors give tips for the caregiver on adapting and implementing the program for people who already have Alzheimer's, decreasing the speed with which symptoms worsen. If Alzheimer's disease is a concern for you or a loved one, The Alzheimer's Prevention and Treatment Diet will give you the information you need to fight back. Using Dr. Isaacson and Dr. Ochner's recommendations, you can put into practice what the evidence is showing us--that what you eat can make all the difference for your mind. |
| columbia alzheimer's study: The Encyclopedia of Alzheimer's Disease Carol Turkington, Deborah R. Mitchell, 2010 In more than 500 entries, The Encyclopedia of Alzheimer's Disease, Second Edition presents a wealth of information on the physical, emotional, and intellectual conditions that affect Alzheimer's sufferers. It also examines the current research on prevention, causes, and treatments, as well as the social issues surrounding the disease. Appendixes include major resources, organizations, helpful books and publications, an extensive bibliography, and a glossary. |
| columbia alzheimer's study: Alzheimer Disease: New Insights for the Healthcare Professional: 2012 Edition , 2012-12-10 Alzheimer Disease: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Alzheimer Disease. The editors have built Alzheimer Disease: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Alzheimer Disease in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Alzheimer Disease: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| columbia alzheimer's study: Manual of Traumatic Brain Injury Felise S. Zollman, MD, 2016-05-28 The Manual provides an excellent road map to the many topics relevant in the diagnosis, treatment, and long-term management of individuals with TBI. As such, the book can serve either as a fine introduction for the uninitiated or as a valued reference for seasoned clinicians. I highly recommend [it]... Journal of Head Trauma Rehabilitation This is a stellar quality book that will be beneficial for every member of the multidisciplinary team that is required to treat patients with TBI. It offers a concise but broad and informative view of the disorder, and can serve as an easy-to-read and access primary text. 4 Stars! Doody’s Reviews Now completely revised and updated, Manual of Traumatic Brain Injury:Assessment and Management, Second Edition is a comprehensive evidence-based guide to brain injury diagnosis, treatment, and recovery, delivered in a succinct format designed for targeted access to essential content. This concise text, featuring internationally known contributors drawn from leading TBI programs, is organized into five sections. Part 1 discusses fundamental concepts needed to provide a context for clinical decision-making. Part 2 covers mild TBI, from natural history to sports-related concussion, post-concussion syndrome, and more. Part 3 focuses on moderate to severe TBI and contains chapters on pre-hospital, emergency and ICU care, rehabilitation, community reintegration, management of associated impairments, and post-injury outcomes. Part 4 covers the complications and long-term sequelae that may arise in patients with TBI, including spasticity, movement disorders, posttraumatic seizures, hydrocephalus, behavioral and sleep disturbances, and chronic traumatic encephalopathy (CTE). Part 5 focuses on special considerations and resources, including issues specific to selected populations or injury environments (military, pediatric, workers compensation and older patients), as well as return to work and medico-legal issues in TBI. Comprehensively updated to reflect the current state of the art in this rapidly evolving field, this book is a must-have for neurologists, physiatrists, primary care physicians, mental health professionals, social workers, and other healthcare providers who treat TBI patients. New to the Second Edition: Key Points section in each chapter crystallizes important clinical pearls New chapters cover anoxia complicating TBI, screening for emotional distress in TBI patients, management of chronic behavioral disturbances, and assistive technology Every chapter has been updated to reflect current evidence-based practice |
| columbia alzheimer's study: Cerebrospinal Fluid Biomarkers Charlotte E. Teunissen, Henrik Zetterberg, 2022-05-19 This volume covers the latest methods used in clinical neurochemistry laboratories for both clinical practice and research. Chapters in this book discuss topics such as techniques for cerebrospinal fluid (CSF) collection, pre-analytical processing, and basic CSF analysis; an examination of biomarkers including ELISA and automated immunochemical assays for amyloid and tau markers for Alzheimer’s disease; the analysis of neurofilaments by digital ELISA; and an example of successful novel immunoassay development. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Cerebrospinal Fluid Biomarkers is a valuable resource for clinicians and researchers to use in CSF labs and CSF courses. |
| columbia alzheimer's study: The Myth of Alzheimer's Peter J. Whitehouse, M.D., Daniel George, M.Sc., Daniel R. George, 2008-12-09 Challenges conventional perceptions about Alzheimer's disease to offer readers alternative approaches to memory loss and aging that can be aided through simple nutritional and exercise strategies. |
| columbia alzheimer's study: Stolen World Jennie Erin Smith, 2011-01-04 Tortoises disappear from a Madagascar reserve and reappear in the Bronx Zoo. A dead iguana floats in a jar, awaiting its unveiling in a Florida court. A viper causes mayhem from Ethiopia to Virginia. In Stolen World, Jennie Erin Smith takes the reader on an unforgettable journey, a dark adventure over five decades and six continents. In 1965, Hank Molt, a young cheese salesman from Philadelphia, reinvented himself as a “specialist dealer in rare fauna,” traveling the world to collect exquisite reptiles for zoos and museums. By the end of the decade that followed, new endangered species laws had turned Molt into a convicted smuggler, and an unrepentant one, who went on to provide many of the same rare reptiles to many of the same institutions, covertly. But Molt soon found a rival in Tommy Crutchfield, a Florida carpet salesman with every intention of usurping Molt as the most accomplished reptile smuggler in the country. Like Molt, Crutchfield had modeled himself after an earlier generation of natural-history collectors celebrated for their service to science, an ideal that, for Molt and Crutchfield, eclipsed the realities of the new wildlife-protection laws. Zoo curators, caught between a desire for rare animals and the conservation-minded focus of their institutions, became the smugglers’ antagonists in court but also their best customers, sometimes simultaneously. Crutchfield forged ties with a criminally inclined Malaysian wildlife trader and emerged a millionaire, beloved by some of the finest zoos in the world. Molt, following a string of inventive but disastrous smuggling schemes in New Guinea, was reduced to hanging around Crutchfield’s Florida compound, plotting Crutchfield’s demise. The fallout from their feud would result in a major federal investigation with tentacles in Germany, Madagascar, Holland, and Malaysia. And yet even after prison, personal ruin, and the depredations of age, Molt and Crutchfield never stopped scheming, never stopped longing for the snake or lizard that would earn each his rightful place in a world that had forgotten them—or rather, had never recognized them to begin with. |
| columbia alzheimer's study: Handbook of Depression in Alzheimer’s Disease G.S. Smith, 2015-08-05 Advances in healthcare have led to an extended life expectancy throughout the developed world, but cognitive impairment in later life, and Alzheimer's disease (AD) in particular, remains one of the intractable problems which can blight quality of life as we age. Depression in Alzheimer's disease is an additional factor which has a significant impact on disability, disease progression, and caregiver burden. This book, volume 4 of the Advances in Alzheimer’s Disease book series which is published in coordination with the Journal of Alzheimer’s Disease, presents papers which reflect the progress in recent years of research into depression in AD. This research has focused on several areas, including the improvement of diagnostic criteria and outcome measures for depression and depressive symptoms in AD, genetic and imaging studies to elucidate the neurobiological mechanisms, and clinical trials of antidepressants. The book is divided into sections on phenomenology, epidemiology, neuropsychology, neurobiology and neuropathology, neuroimaging, genetics, and treatment. Providing a stimulus to further research in this challenging area by engaging both basic and clinical researchers, this book will be of interest to all those whose work involves understanding and dealing with depression in those suffering from Alzheimer's disease. |
| columbia alzheimer's study: The Memory Program D. P. Devanand, 2001-05-29 We all have concerns about our memories about becoming forgetful, about how to preserve our memories especially as we age. Now, Dr. D. P. Devanand answers your questions about memory loss due to aging and offers a revolutionary, medically sound practical program to keep your mind in shape and stave off memory loss. The Memory Program is a complete promemory plan for everyone over 40 learn how memory works in the brain and how aging affects your memory evaluate your memory using simple tests follow the right diet and exercise plan to help your memory * Use special memory-training techniques to keep your mind sharp * Tackle the major reversible causes of memory loss including stress and depression, alcohol, medications, and hormonal and nutritional problems * Discover exciting new preventive strategies and treatments, including herbal and other alternative medications, antioxidants and nutritional supplements, and useful over-the-counter and prescription medicines. Personalized by gender, age group, and whether you currently have a normal memory or suffer from mild memory loss, The Memory Program is a comprehensive, simple-to-follow plan to enhance your memory. Its the only memory book youll ever need. |
Metformin in Alzheimer’s dementia Prevention (MAP)
cognitive decline associated with Alzheimer’s dementia, we will compare changes over 18 months in verbal memory performance, measured with the Total Recall Score of the Free and Cued …
Newly found genetic variant defends against Alzheimer's …
Columbia researchers have discovered a genetic variant that reduces the odds of developing Alzheimer's disease by up to 70% and may be protecting thousands of people in the United …
Effect of multivitamin-mineral supplementation versus …
Oct 13, 2023 · Objectives: This study aimed to test MVM effects on cognitive change using in-person, detailed neuropsychological assessments and conduct a meta-analysis within …
Meta-Analysis of the Alzheimer’s Disease Human Brain …
We present a consensus atlas of the human brain transcriptome in Alzheimer’s disease (AD), based on meta-analysis of differential gene expression in 2,114 postmortem samples. We …
Journal of Alzheimer’s Disease xx (2020) x–xx IOS Press …
May 16, 2021 · Alzheimer’s disease (AD) including impaired cognition, amyloid- plaques, neurofibrillary tangles, diminished glucose metabolism, oxidative stress, increased advanced …
Functional MRI Data Deep Learning Identies ... - Columbia …
We screened T1W MRI scans from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset, selected for 3 Tesla MP-RAGE acquisitions, and performed propensity score …
Correlation of plasma and neuroimaging biomarkers in …
Our results add to increasing evidence that plasma Ptau 181 and 217 concentrations are valid Alzheimer’s disease biomarkers in diverse populations.
Alzheimer s Biomarkers Consortium of Down Syndrome (ABC …
Alzheimer’s Biomarkers Consortium of Down Syndrome (ABC -DS) • Two multi-site studies supported by NIA and NICHD • Neurodegeneration in Aging Down Syndrome ( NiAD) • …
Risk of Alzheimer’s Disease is Associated with Longitudinal
Aug 11, 2023 · INTRODUCTION: Alzheimer’s disease (AD) biomarkers can help differentiate cognitively unimpaired (CU) individuals from mild cognitive impairment (MCI) and dementia. …
arXiv:2412.08088v1 [stat.ME] 11 Dec 2024
the gold-standard neuropathological diagnoses of Alzheimer’s disease (AD) and Lewy body dementia (LBD) are only available through postmortem autopsy, making them inaccessible …
Yaakov Stern, PhD - Columbia University
Dr. Stern also leads a large scale imaging study to identify unique neural networks underlying the major cognitive abilities affected by aging, and another long-term study that models the natural …
Increased Risk of Mortality in Alzheimer's Disease Patients …
A reserve hypothesis suggests that clinical symptoms of Alzheimer's disease (AD) begin earlier in individuals with less education. Therefore, patients with less education might survive longer …
CLINICAL TRIAL PROTOCOL
multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to …
Scales as outcome measures for Alzheimer•s disease
Mar 25, 2009 · In recognition of the need to review and possibly revise current assessment measures, the Alzheimer’s Association, in cooperation with industry leaders and academic …
BUTLER HOSPITAL’S MEMORY AND AGING PROGRAM …
This study aims to validate AD biomarker indicators in individuals who are healthy, yet may have a higher risk for developing AD. The study will also use these and other metrics to form …
The Columbia Suicide Severity Rating Scale (C-SSRS)
Jan 31, 2022 · The Columbia Suicide Severity Rating Scale (C-SSRS): Psychometric Evidence Table 1: Studies Supporting Specific Psychometric Properties of the Full Version * studies …
Metformin in the Prevention of Alzheimer’s Disease and …
Metformin is a safe and effective medication for Type 2 diabetes (T2D) that has been proposed to decrease the risk of aging related disorders including Alzheimer’s Disease (AD) and AD …
Cognitive reserve in ageing and Alzheimer's disease - The …
In this Personal View I present a theoretical account of cognitive reserve, summarise epidemiological research that has lent support to the concept, and describe imaging studies …
Cognitive Reserve and Alzheimer Disease - Academic Commons
Abstract: Epidemiologic evidence suggests that individuals with higher IQ, education, occupational attainment, or participation in leisure activities have a reduced risk of developing Alzheimer …
Karen S. Marder, M.D. M.P.H. - Columbia University
Marder’s research interests span a range of neurodegenerative diseases including Parkinson’s disease, Huntington’s disease, HIV dementia, and Alzheimer’s disease. She is the principal …
Metformin in Alzheimer’s dementia Prevention (MAP)
cognitive decline associated with Alzheimer’s dementia, we will compare changes over 18 months in verbal memory performance, measured with the Total Recall Score of the Free and Cued …
Newly found genetic variant defends against Alzheimer's …
Columbia researchers have discovered a genetic variant that reduces the odds of developing Alzheimer's disease by up to 70% and may be protecting thousands of people in the United …
Effect of multivitamin-mineral supplementation versus …
Oct 13, 2023 · Objectives: This study aimed to test MVM effects on cognitive change using in-person, detailed neuropsychological assessments and conduct a meta-analysis within …
Meta-Analysis of the Alzheimer’s Disease Human Brain …
We present a consensus atlas of the human brain transcriptome in Alzheimer’s disease (AD), based on meta-analysis of differential gene expression in 2,114 postmortem samples. We …
Journal of Alzheimer’s Disease xx (2020) x–xx IOS Press …
May 16, 2021 · Alzheimer’s disease (AD) including impaired cognition, amyloid- plaques, neurofibrillary tangles, diminished glucose metabolism, oxidative stress, increased advanced …
Functional MRI Data Deep Learning Identies ... - Columbia …
We screened T1W MRI scans from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset, selected for 3 Tesla MP-RAGE acquisitions, and performed propensity score …
Correlation of plasma and neuroimaging biomarkers in …
Our results add to increasing evidence that plasma Ptau 181 and 217 concentrations are valid Alzheimer’s disease biomarkers in diverse populations.
Alzheimer s Biomarkers Consortium of Down Syndrome …
Alzheimer’s Biomarkers Consortium of Down Syndrome (ABC -DS) • Two multi-site studies supported by NIA and NICHD • Neurodegeneration in Aging Down Syndrome ( NiAD) • …
Risk of Alzheimer’s Disease is Associated with Longitudinal
Aug 11, 2023 · INTRODUCTION: Alzheimer’s disease (AD) biomarkers can help differentiate cognitively unimpaired (CU) individuals from mild cognitive impairment (MCI) and dementia. …
arXiv:2412.08088v1 [stat.ME] 11 Dec 2024
the gold-standard neuropathological diagnoses of Alzheimer’s disease (AD) and Lewy body dementia (LBD) are only available through postmortem autopsy, making them inaccessible …
Yaakov Stern, PhD - Columbia University
Dr. Stern also leads a large scale imaging study to identify unique neural networks underlying the major cognitive abilities affected by aging, and another long-term study that models the natural …
Increased Risk of Mortality in Alzheimer's Disease Patients …
A reserve hypothesis suggests that clinical symptoms of Alzheimer's disease (AD) begin earlier in individuals with less education. Therefore, patients with less education might survive longer …
CLINICAL TRIAL PROTOCOL
multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to …
Scales as outcome measures for Alzheimer•s disease
Mar 25, 2009 · In recognition of the need to review and possibly revise current assessment measures, the Alzheimer’s Association, in cooperation with industry leaders and academic …
BUTLER HOSPITAL’S MEMORY AND AGING PROGRAM …
This study aims to validate AD biomarker indicators in individuals who are healthy, yet may have a higher risk for developing AD. The study will also use these and other metrics to form …
The Columbia Suicide Severity Rating Scale (C-SSRS)
Jan 31, 2022 · The Columbia Suicide Severity Rating Scale (C-SSRS): Psychometric Evidence Table 1: Studies Supporting Specific Psychometric Properties of the Full Version * studies …
Metformin in the Prevention of Alzheimer’s Disease and …
Metformin is a safe and effective medication for Type 2 diabetes (T2D) that has been proposed to decrease the risk of aging related disorders including Alzheimer’s Disease (AD) and AD …
Cognitive reserve in ageing and Alzheimer's disease - The …
In this Personal View I present a theoretical account of cognitive reserve, summarise epidemiological research that has lent support to the concept, and describe imaging studies …
Cognitive Reserve and Alzheimer Disease - Academic …
Abstract: Epidemiologic evidence suggests that individuals with higher IQ, education, occupational attainment, or participation in leisure activities have a reduced risk of developing Alzheimer …
Karen S. Marder, M.D. M.P.H. - Columbia University
Marder’s research interests span a range of neurodegenerative diseases including Parkinson’s disease, Huntington’s disease, HIV dementia, and Alzheimer’s disease. She is the principal …
